Recently, SNEURO MEDICAL, a platform-level leading enterprise in China's neuromodulation and brain-computer interface field, announced the completion of a C-round financing worth hundreds of millions of RMB. This round of financing was led by Legend Capital, with previous shareholders OrbiMed, Boyuan Capital, and SDIC Innovation all significantly increasing their investments.
Notably, Legend Capital's investment in the brain-computer interface sector is not an isolated case—earlier this year, it co-led a Series A funding round of over 300 million yuan for SNEURO MEDICAL, an invasive brain-computer interface company, demonstrating its continued commitment and strong confidence in this cutting-edge field.
It is reported that the funds raised in this round will be mainly used to accelerate the innovative iteration and global commercialization layout of the company's "Ultra-Micro Neurostimulation Technology Platform" and "Brain-Computer Interface Platform." Established in 2018, SNEURO MEDICAL is a leading platform enterprise in the field of neurostimulation and brain-computer interface in China. The company focuses on the research and development of active neural implantable medical devices, primarily targeting two types of Class III medical devices: Spinal Cord Stimulation (SCS) and short-term implantable Peripheral Nerve Stimulation (PNS), which are used for treating chronic pain, epilepsy, heart failure, and other conditions. It also possesses core technologies such as rechargeable implantable pulse generators, wireless power transfer, and adaptive closed-loop stimulation, holding over 150 patents and software copyrights both domestically and internationally.
Relying on its unique "platform-based" innovation engine, SNEURO MEDICAL has become one of the few companies globally to simultaneously master three core technologies: short-term implantation, rechargeable IPG, and wireless power transmission.
Currently, the company has built a strong product portfolio: the implantable spinal cord stimulation (SCS) system was approved for marketing by the National Medical Products Administration in early 2026; the short-term peripheral nerve stimulation (PNS) system has entered the registration application stage, which will fill the gap in the Chinese market and form a comprehensive solution for chronic pain together with the SCS system.
In the direction of ultra-miniaturization, the company has laid out a tibial nerve stimulation (TNS) system for urinary dysfunction and a Micro-SCS/PNS system. With globally leading miniaturized design and clinical trial data performance, it continues to lead industry trends.
At the same time, based on the solid foundation of neuromodulation, the company is developing a new generation of closed-loop brain-computer interface systems for neural function reconstruction, aiming to provide a disruptive solution for restoring motor functions in patients with severe conditions such as spinal cord injury.
It is reported that in the future, the company will also launch a series of innovative therapies such as the obstructive sleep apnea (OSA) hypoglossal nerve stimulation system, to build a comprehensive neuromodulation solution covering multiple indications.
Notably, with the completion of this Series C round of financing, SNEURO MEDICAL's cumulative financing amount is expected to exceed 1 billion yuan, setting a new record for both the scale of financing and valuation in China's neuromodulation sector.
Since the Pre-A round, the company has maintained a steady financing pace, attracting continuous investment from top-tier domestic and international institutions such as Legend Capital, OrbiMed, BioTrack Capital, SDIC Venture Capital, and CICC Capital. This fully demonstrates the capital market's high recognition of its technology platform, product pipeline, and commercialization prospects.
Its technology is based on an innovative neuromodulation platform, and its products are currently in the research and development and registration application stage. This round of financing will accelerate the advancement of clinical trials and industrialization layout.
